CN Patent

CN103502217B — 包含酪氨酸激酶抑制剂的二芳基乙炔酰肼

Assigned to Sun Pharmaceutical Industries Ltd · Expires 2015-11-25 · 10y expired

What this patent protects

本发明涉及作为酪氨酸激酶抑制剂的式(I)的新型二芳基乙炔酰肼化合物或其药学上可接受的盐，它们的制备方法，并且涉及式(I)的化合物在制备用于治疗学治疗温血动物中与酪氨酸激酶有关的疾病的药物组合物中的用途。

USPTO Abstract

本发明涉及作为酪氨酸激酶抑制剂的式(I)的新型二芳基乙炔酰肼化合物或其药学上可接受的盐，它们的制备方法，并且涉及式(I)的化合物在制备用于治疗学治疗温血动物中与酪氨酸激酶有关的疾病的药物组合物中的用途。

Drugs covered by this patent

ponatinib-hydrochloride (PONATINIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN103502217B
Jurisdiction: CN
Classification: —
Expires: 2015-11-25
Drug substance claim: No
Drug product claim: No
Assignee: Sun Pharmaceutical Industries Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.